biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Where are the links?

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Jan 03, 2025 9:11pm

121 Views

Post# 36387070

RE:RE:RE:Where are the links?

Again, you have failed to provide xb3 was successful. After 10+ years, they never end made it out of precinical trials. That is a joke and very telling. They did have several companies at least look at their technology and they passed. What you refuse to accept is that the platform was deemed as having no utility. If there was any value to their platform, big pharma would have bought it and developed it themselves and not have to deal with bti management. I can't imagine you are that naive.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management